CEO succession

Omega Diagnostics Group PLC

("Omega" or the "Company")

CEO succession

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that as part of Omega's Board succession planning, Andrew Shepherd has agreed to step down as Chief Executive Officer and from the Board with immediate effect. He will remain with the Group in the role of Global Ambassador- Life President. Andrew will be succeeded by Colin King, currently Chief Operating Officer of the Group.

Andrew founded Omega in 1987 and built up an extensive distribution network in over 100 countries. In September 2006, Andrew led the Company through its successful IPO and has been instrumental in growing the Group since its first acquisition of Genesis Diagnostics and Cambridge Nutritional Sciences in August 2007.

David Evans, Chairman of Omega, commented: "Firstly, I would like to thank Andrew for not only establishing Omega over thirty years ago but for his passion and commitment to the business since then. Andrew commands a huge amount of respect both internally and externally and I am hoping that in his new role as Global Ambassador for the Company that respect will make the process of adaptation easier and allow Andrew to help the Company deliver on his and the Company's vision for CD4 in particular.

"Secondly, a transition of this nature is one that all of us recognise will have its challenges as employees, customers and partners adjust to Andrew undertaking a different role. It also brings new opportunities for the Company and I believe we can capitalise upon these in the months ahead.

"Thirdly, Colin King, who was brought into the Company in 2015 as part of a planned succession process will now have the opportunity to drive Omega onto the next level. The challenges in front of us are obvious and I know that Colin is up for the challenge and that he, along with all of us at Omega will deliver in a meaningful way for the benefit of all stakeholders."

Andrew Shepherd, former CEO, commented: "The last 30 years have been a real mix of excitement and challenges and some disappointments of course. It has been an absolute pleasure to experience Omega corporate life and the science that we use on a daily basis, and to create and investigate new opportunities and interactions with so many people around the world. The Company is now moving into an accelerated growth phase and there are some very exciting times ahead, especially with the launch of Visitect®CD4. With Colin's appointment as CEO I feel he is very capable of delivering the next phase of growth and I wish him all the best with the task ahead."

Colin King, CEO commented: "It's a great privilege and honour to follow Andrew as CEO of Omega after building the Company over the past 30 years. Although we have some short term challenges, I firmly believe that we can deliver our accelerated growth strategy to the benefit of all stakeholders and I will do my utmost to ensure the Company's success."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts: